UY39303A - Inhibidores de mutación her2 - Google Patents
Inhibidores de mutación her2Info
- Publication number
- UY39303A UY39303A UY0001039303A UY39303A UY39303A UY 39303 A UY39303 A UY 39303A UY 0001039303 A UY0001039303 A UY 0001039303A UY 39303 A UY39303 A UY 39303A UY 39303 A UY39303 A UY 39303A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- salts
- her2 mutation
- enantiomers
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I): (I),y enantiómeros de estos, y a sales farmacéuticamente aceptables de la fórmula (I) y dichos enantiómeros, en donde L1, L2, R1, R2, R3 y n son como se definen en el presente documento. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos y usos de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer, en un sujeto que lo necesite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046506P | 2020-06-30 | 2020-06-30 | |
| US202163208901P | 2021-06-09 | 2021-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39303A true UY39303A (es) | 2022-01-31 |
Family
ID=76797050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039303A UY39303A (es) | 2020-06-30 | 2021-06-29 | Inhibidores de mutación her2 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11834453B2 (es) |
| TW (1) | TW202214641A (es) |
| UY (1) | UY39303A (es) |
| WO (1) | WO2022003575A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| AU2023243776A1 (en) | 2022-03-28 | 2024-09-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof |
| US20240279230A1 (en) | 2022-12-22 | 2024-08-22 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| BRPI0413565B8 (pt) | 2003-08-14 | 2021-05-25 | Array Biopharma Inc | análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica |
| US8648087B2 (en) * | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| EP3677583A4 (en) | 2017-09-01 | 2021-07-21 | Shanghai Pharmaceuticals Holding Co., Ltd. | NITROGEN HETEROCYCLIC COMPOUND, MANUFACTURING PROCESS, INTERMEDIATE, COMPOSITION AND USE |
| ES2971927T3 (es) | 2018-09-18 | 2024-06-10 | Hoffmann La Roche | Derivados de quinazolina como agentes antitumorales |
| WO2021127397A1 (en) | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| WO2021156180A1 (en) * | 2020-02-03 | 2021-08-12 | Boehringer Ingelheim International Gmbh | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| US20230126204A1 (en) * | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| US20230265098A1 (en) | 2020-07-02 | 2023-08-24 | Enliven Therapeutics, Inc. | Alkyne quinazoline derivatives as inhibitors of erbb2 |
| WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022266458A1 (en) | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-heterocycloalkyl-quinazoline derivatives and uses thereof |
| WO2022269531A1 (en) | 2021-06-26 | 2022-12-29 | Array Biopharma Inc. | Her2 mutation inhibitors |
-
2021
- 2021-06-25 TW TW110123381A patent/TW202214641A/zh unknown
- 2021-06-29 WO PCT/IB2021/055832 patent/WO2022003575A1/en active Application Filing
- 2021-06-29 US US17/362,580 patent/US11834453B2/en active Active
- 2021-06-29 UY UY0001039303A patent/UY39303A/es unknown
-
2023
- 2023-11-01 US US18/499,669 patent/US20240124474A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202214641A (zh) | 2022-04-16 |
| US11834453B2 (en) | 2023-12-05 |
| WO2022003575A1 (en) | 2022-01-06 |
| US20240124474A1 (en) | 2024-04-18 |
| US20230023851A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38553A (es) | Inhibidores de cdk2 | |
| CO2021017504A2 (es) | Derivados de benzisoxazol sulfonamida | |
| DOP2023000281A (es) | Inhibidores de mutación de her2 | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| DOP2020000191A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina | |
| UY39303A (es) | Inhibidores de mutación her2 | |
| CO2022016377A2 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
| ECSP22033597A (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
| UY39193A (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| ECSP23083562A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| UY39517A (es) | Inhibidores de la btk | |
| CO2023012702A2 (es) | Derivados de diazepina útiles en el tratamiento de clostridium difficile | |
| DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 | |
| AR122805A1 (es) | Inhibidores de mutación her2 | |
| EA202191818A1 (ru) | 3-карбониламино-5-циклопентил-1h-пиразольные соединения, обладающие ингибирующей активностью в отношении cdk2 | |
| AR126238A1 (es) | Inhibidores de mutación de her2 | |
| DOP2024000096A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| MX2020004871A (es) | Derivados de acido cafeico y sus usos. |